Associate Professor
BA University of Pennsylvania 1987; MD, Yale University 1992
School of Medicine
Medicine
Infectious Diseases
Division of Infectious Diseases
- I have two primary research interests. The first is on HIV-HBV coinfection where I have projects in Nigeria, Australia and the United States. In addition, I am leading a multicenter international study looking at HIV-HBV co-infection within the ACTG framework.
-
My second area is on the human genetic determinants of HBV and HCV clearance where I examine polymorphisms in human genes in persons that have either recovered from or have a persistent viral hepatitis infection.
- hepatitis B, hepatitis C, genetics, HIV-HBV coinfection
Research Projects
A5175: Nested study of the treatment of chronic hepatits B in HIV infected persons
The purpose of this study is to test the hypothesis that treatment of chronic hepatits B in HIV infected persons is more efficacious with Truvada compared to either lamivudine or emtricitabine alone. We are also investigating the development of drug-resistant virus.
Hepatitis B treatment and HIV Infection in resources limited settings
Chronic hepatitis B (CH-B), which is the leading cause of end stage liver disease and hepatocellular carcinoma worldwide, affects an estimated 10% of HIV-infected persons. The current options for treating CH- B have poor efficacy. As antiretroviral therapy is introduced into areas with the...
Liver Disease and HIV-HBV Coinfection in the HAART era
Chronic hepatitis B (CH-B) is common in HIV-infected persons, and HIV accelerates the rate of hepatitis B-related liver disease progression. In the Multicenter AIDS Cohort Study (MACS), the risk of liver-related death was nearly 18 times higher in those coinfected with HIV-HBV compared to those...
NIH/Johns Hopkins Bench to Bedside Project: Hepatitis B and HIV Co-Infection
The NIH Bench to Bedside program provides a unique opportunity to develop a systematic research program to improve understanding and management of HIV and hepatitis B (HBV) co-infection, from ‘bench’ to ‘bedside’ to ‘bush’. Building on the existing NIH/NIAID International Center for Excellence in...
- Rauch A, Graudieri S, Thio CL, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics, in press.
-
2.
-
Thio CL. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV co-infected patients on HAART. Antiviral Therapy, in press.
-
Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy, 2009, in press.
-
Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, Sankale J-L, Ekong E, Murphy R, Kanki P, Thio CL. Impact of hepatitis B virus infection on HIV response to antiretroviral therapy in Nigeria. CID, 2009, in press. NIHMS 130120.
-
Hoffmann CJ, Seaberg EC, Young S, Witt MD, D’Acunto K, Phair J, Thio CL. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS, 2009, in press.
-
Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology, 2009 April; 49(S5): S138-S145.
-
Matthews GV, Seaberg EC, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, Marks P, Hoy J, Finlayson R, Goodman Z, Philp FH, Tang Y, Locarnini SA, Thio CL. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV co-infected individuals. AIDS, 2009 Aug 24;23(13):1707-15.
-
Gu Y, Harley IT, Henderson LB, Aronow BJ, Vietor I, Huber LA, Harley JB, Kilpatrick JR, Langefeld CD, Williams AH, Jegga AG, Chen J, Wills-Karp M, Arshad SH, Ewart SL, Thio CL, Flick LM, Filippi MD, Grimes HL, Drumm ML, Cutting GR, Knowles MR, Karp CL. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature, 2009 Apr; 458(7241):1039-42.
-
Hoffmann CJ, Charalambous J, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant AD, Fielding KL, Thio CL. Hepatitis B Virus Infection and Response to Antiretroviral Therapy (ART) in a South African ART Program. CID, 2008 Dec; 47(11): 1479-85.
-
Thio CL, Astemborski J, Thomas R, Mosbruger T, Witt MD, Goedert JJ, Hoots K, Winkler C, Thomas DL, Carrington M. Interaction between RANTES promoter variant and CCR5?32 favors recovery from hepatitis B. JI, 2008 Dec; 181(11):7944-7.
-
An P, Thio CL, Kirk GD, Donfield S, Goedert JJ, Winkler CA. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C clearance. JID, 2008 Oct; 198(8):1159-65.
-
Preiss S, Littlejohn M, Angus P, Thompson A, Desmond P, Lewin SR, Sasadeusz J, Matthews G, Dore GJ, Shaw T, Sozzi V, Yuen L, Lau G, Ayres A, Thio C, Avihingsanon A, Ruxrungtham K, Locarnin S, Revill PA. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology, 2008, Sept; 48(3):741-9.
-
Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS, 2008 May 11;22(8):947-55.
-
Domaoal RA, McMahon M, Thio CL, Bailey CM, Tirado-Rives J, Obikhod A, Detorio M, Rapp KL, Silicano RF, Schinazi RF, Anderson KS. Pre-steady state kinetic studies establish entecavir 5’-triphosphate as a substrate for HIV-1 reverse transcriptase. JBC, 2008 Feb 29;283(9):5452-9.
-
McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. NEJM 2007, 356(25):2614-21.
|
|
